Retatrutide

What it is

Retatrutide is the most powerful metabolic peptide in clinical development, and it earns that title with a genuinely new mechanism. Where semaglutide hits one receptor and tirzepatide hits two, retatrutide is the first molecule to activate three at once: GLP-1, GIP, and glucagon. Two of those receptors turn calories-in down; the third turns calories-out up. That third lever — the glucagon arm — is why retatrutide does something the earlier drugs can’t.

If you’ve watched a GLP-1 plateau in yourself or someone you know — fast progress for nine months, then the scale freezes and the cravings creep back — retatrutide is the answer the field built for exactly that wall. In the pivotal Phase 2 obesity trial, people losing weight without dieting or structured exercise still dropped up to 24.2% of body weight at 48 weeks [PMID 37366315]. That is the largest weight-loss effect ever recorded for a non-surgical agent, and the curve doesn’t flatten the way the earlier drugs’ curves do.

This is a tool, and it’s a remarkable one. Used well — with protein, resistance training, and intelligent dosing — it’s a metabolic reset that can move markers most people thought required surgery. The rest of this article gives you what you need to use it well.

How it works

Three receptors, three jobs:

GLP-1 receptor — satiety + glucose. Same target as semaglutide. In the brain it lowers appetite and slows gastric emptying (food sits longer, you feel full sooner, you eat less); in the pancreas it amplifies glucose-dependent insulin release [PMID 41054801].

GIP receptor — fat handling + insulin sensitivity. Tirzepatide’s added receptor. GIP improves how fat tissue stores and releases energy and supports adipocyte function — part of why dual and triple agonists out-body-comp the pure GLP-1 drugs [PMID 41054801].

Glucagon receptor — energy expenditure, the new lever. This is where retatrutide breaks from the pack. Glucagon agonism in the liver and brown fat raises energy expenditure and drives fat oxidation rather than just suppressing intake — your body burns more, not only eats less. As clinician-educators Williams and Froese both describe it: the glucagon arm increases resting energy expenditure, suppresses de-novo lipogenesis (new fat made from carbs), and directly burns liver fat. Normally glucagon would raise blood sugar, but the GLP-1/GIP arms keep insulin secretion robust, so the fat-burning effect runs largely unopposed.

That third receptor is the answer to “why does this break the plateau.” On pure GLP-1 drugs, part of the plateau is your body downshifting its metabolic rate to defend the calorie deficit. The glucagon agonist counters that downshift. Mechanistically, β-hydroxybutyrate rose 2–3 fold (dose-related, without ketoacidosis) in the MASLD trial — a fingerprint of your body shifting to burning fat for fuel (Nature Medicine 2024, PMC11271400).

What the research shows

Retatrutide has unusually strong human evidence for an investigational compound — the base is dominated by randomized trials and RCT-pooled meta-analyses, a far better profile than most peptides in this space.

Human RCT — strongest first:

• Phase 3 TRIUMPH program (topline, company-reported Dec 2025 – May 2026; full publications pending). TRIUMPH-1, the pivotal general-obesity trial (80 wk; adults with obesity/overweight without T2D), reported mean weight loss of −19.0% (4 mg), −25.9% (9 mg), and −28.3% (12 mg) — and 45.3% of the 12 mg group lost ≥30%, bariatric-surgery territory — with a BMI ≥35 extension reaching −30.3% (~85 lb) at 104 weeks. TRIUMPH-4 (68 wk, n=445, the knee-osteoarthritis + obesity trial, NCT05931367) reported up to −28.7% weight loss and was the first Phase 3 readout (Dec 2025). TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obstructive sleep apnea) round out the >5,800-participant program; TRIUMPH-1 is the trial carrying the weight-management NDA. These are topline figures from Lilly investor/conference releases — pin the full peer-reviewed publications before any customer-facing use.
• Phase 3 TRIUMPH-4 — knee osteoarthritis (topline, design paper PMID 41090431, DOI 10.1111/dom.70209; full efficacy publication pending). In adults with BMI ≥27 and knee OA (no T2D), retatrutide met both primary endpoints: alongside the −28.7% weight loss, the 12 mg arm cut WOMAC knee-pain scores by 75.8% (mean −4.5 points), with 12.0% of the 12 mg group completely pain-free vs 4.2% on placebo and more than half hitting the ≥50%-pain-reduction secondary endpoint. This is the first Phase-3-grade evidence that the weight loss translates into a measurable joint-function/recovery benefit — the basis for retatrutide’s secondary heal-recover relevance (weight offloading + the GLP-1 anti-inflammatory signal). Verified against primary sources.
• Phase 2 obesity RCT (Jastreboff/NEJM 2023, n=338) [PMID 37366315] — at 48 weeks, least-squares mean weight change was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg) vs −2.1% placebo. At 12 mg, 100% lost ≥5%, 93% lost ≥10%, 83% lost ≥15%. GI events were dose-related and mostly mild-to-moderate; lower starting doses mitigated them.
• Phase 2 T2D RCT (Rosenstock/Lancet 2023, n=281) [PMID 37385280] — retatrutide produced dose-dependent HbA1c reductions and weight loss in type-2 diabetes. The active comparator in this trial was dulaglutide, not metformin — worth stating plainly, because the popular “67% reached HbA1c <5.7% on retatrutide vs 18% on metformin” framing misattributes the comparator (citation-verification pass 0018); anchor any T2D/glucose claim to this trial, not a metformin head-to-head.
• Phase 2a MASLD RCT (Sanyal/Nature Medicine 2024, n=98; PMID 38858523 / PMC11271400) — relative liver-fat reduction of −81.7% (8 mg) and −86.0% (12 mg) vs −4.6% placebo at 48 weeks; 89% (8 mg) and 93% (12 mg) reached normal liver fat (<5%). No hepatotoxicity signals.
• Bayesian network meta-analysis (Sinha & Ghosal 2025, 19 RCTs, n=29,506) [PMID 40685589] — retatrutide had the highest odds of ≥15% weight loss in class (OR 54.6 vs placebo), ahead of dual agonists (OR 16.4) and GLP-1 RAs (OR 9.0).
• Network meta-analysis (Xie 2024, 27 RCTs) [PMID 39305981] — retatrutide 12 mg (−22.1% body weight, −17.0 cm waist) and 8 mg (−20.7%) ranked first and second of all agents reviewed; tirzepatide 15 mg third. No agent significantly raised serious adverse events or hypoglycemia.
• Systematic review (Moiz/Annals 2025, 26 RCTs) [PMID 39761578] — retatrutide 12 mg produced up to 22.1% weight loss at 48 weeks, the highest of any agent, exceeding tirzepatide (17.8%) and semaglutide (13.9%).
• Meta-analysis (Abouelmagd 2025, 3 RCTs, n=878) [PMID 40291085] — significant reductions in weight (−14.33%), BMI, waist, fasting glucose (−23.51 mg/dL), HbA1c (−0.91%), and blood pressure; no significant difference in overall adverse-event rate vs placebo.

The clinician-reported longevity markers (Williams’s masterclass, from the 12 mg trial data, against the underlying Lilly publications): ~82% liver-fat reduction, 40% triglyceride reduction, 24% apoB reduction, 22% LDL reduction, ~10-point systolic BP drop, 72% of pre-diabetics returning to normal glucose, and fasting insulin cut by half or more at higher doses. The apoB number is the standout for the longevity audience — apoB is the gold-standard atherosclerosis-risk marker.

Animal data (first-class evidence for where this molecule’s mechanism is mapped):

• GIPR:GCGR co-agonism restored normal weight in obese rodents even with GLP-1 signaling absent — direct proof that GLP-1 alone doesn’t account for the result; the other two arms carry real independent weight. (Mechanism study; verify exact —.)
• Retatrutide improved steatohepatitis in a diet-induced mouse model [PMID 41056349] — reduced body weight, ALT, hepatic triglycerides/cholesterol, and inflammatory markers over a 2-week intervention.

Where experts and studies disagree — shown honestly: Williams reads the dose-response curve as continuing to climb (12 mg/68 wk = 28.7%, which he calls the largest mean weight loss in any obesity trial). One practitioner reads it as plateauing around 4–8 mg, citing roughly 17.5% at 4 mg and ~18% at 8 mg — “a 5% difference for double the dose.” Both agree on the practical takeaway: don’t chase the top of the curve. The honest reconciliation is that the marginal gain from 8→12 mg is small (the NEJM data show 22.8% → 24.2%) and the side-effect cost is large.

What’s still open: Phase 3 TRIUMPH has now read out topline-positive (TRIUMPH-1 and TRIUMPH-4), but the full peer-reviewed publications are not yet out — the headline Phase 3 percentages above are company-reported and tagged for verification; TRIUMPH-2 (T2D) and TRIUMPH-3 (CVD) are still pending. Still no liver-biopsy fibrosis data; durability past ~104 weeks unknown; trial populations skew white, US, non-diabetic. And the body-comp asterisk that matters most: roughly a quarter of weight lost can be lean mass if you don’t train and eat protein — which is exactly why the protocol below is non-negotiable on those two points.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Reconstitution (objective math). A 10 mg vial reconstituted with 2 mL bacteriostatic water gives 5 mg/mL. On a U-100 insulin syringe (100 units = 1 mL), that’s 0.5 mg per 10 units:

• 0.5 mg = 10 units · 1 mg = 20 units · 1.5 mg = 30 units · 2 mg = 40 units
• Inject the water slowly down the side of the vial, swirl gently (never shake — shaking denatures peptide), store reconstituted in the fridge in the dark.

Two user types (Williams’s framework, the cleanest split in this space):

• Weight-loss user — BMI 27+, goal 15–30% body-weight loss. Higher doses, full titration, longer time on.
• Longevity / metabolic-optimization user — normal BMI, goal is moving the markers (insulin sensitivity, liver fat, lipids, apoB, BP, inflammation). Low dose, often microdose; weight loss is modest but the metabolic gains are well preserved.

Standard titration (weight-loss user, Williams):

Weeks	Dose	Note
1–4	2 mg/wk	Never start higher
5–8	4 mg/wk	If needed
9–12	6 mg/wk	If needed
13–17	8 mg/wk	Sweet-spot ceiling for most users
(rare)	12 mg/wk	Severe obesity / non-response only

Where experts differ on the start: one practitioner starts lower and gentler — 0.5 mg/wk for weeks 1–2, double to 1 mg, then step up ~0.5 mg every two weeks — which suits a lean or side-effect-sensitive user. Williams’s 2 mg start matches the obesity-trial starting point. Both are valid; pick by user profile. Lean longevity start: 1 mg/wk, hold 4 weeks, increase to 2 mg only if needed — most lean users find their working dose at 2–4 mg.

Frequency. Once weekly matches the trials (4:1 peak-to-trough, some end-of-week hunger). Splitting to twice weekly cuts the peak ~28% and three-times-weekly ~38%, smoothing appetite and lowering injection-day nausea — PK-modeled, not trial-validated, but widely reported as a smoother ride. Morning vs night is pharmacokinetically a wash (a 6-day half-life means <15% swing across 24 hours) — pick the timing that lands the 4–24-hour side-effect window where it bothers you least.

Cheat-sheet convention (a commonly used practitioner protocol): 10 mg vial in 2 mL, 0.5–1 mg dosed AM, 3–4×/week — note this is a lower weekly exposure than the once-weekly trial protocol; it reflects a split-dosing, lower-dose approach.

Tirzepatide → retatrutide crossover (don’t jump same-dose): walk Tirz down 15 → 10 → 5 → 2 mg, cross to 2 mg Reta, re-titrate up. 4–8 weeks. Skipping the walk-down is the #1 cause of a GI catastrophe on the switch.

Cycling. Three honest models: chronic (indefinite, for those who won’t change lifestyle), cycled/“blast-and-cruise” (6–12 month active windows + maintenance taper), and pulsed (12–24 week cycles even at goal, for liver-fat/lipid benefit). Roughly 76% of weight loss is regained within ~23 weeks of stopping cold, so plan a taper (drop every 4 weeks, e.g., 8→6→4→2→off) and a maintenance dose rather than a hard stop.

🚨 Hard rule — never stack with another GLP-1 receptor agonist. Do NOT combine Retatrutide with Semaglutide (Ozempic / Wegovy), Tirzepatide (Mounjaro / Zepbound), Liraglutide, or any other GLP-1 receptor agonist. All of these molecules bind the same GLP-1 receptor (and Retatrutide additionally adds GIP and glucagon arms). Stacking them double-binds the receptor and compounds the entire side-effect tail — GI severity, hypoglycemia risk, gallstone and pancreatic stress, dehydration, electrolyte loss, and heart-rate effects all stack — without a corresponding compounding of the weight-loss benefit. Pick one drug in this class and titrate it slowly. The protocol builder on this site enforces this rule and will warn you if you try to combine them. This applies across the whole class: semaglutide ⨯ tirzepatide, semaglutide ⨯ retatrutide, tirzepatide ⨯ retatrutide — none of these combinations are safe or productive.

Stacking. Williams and Jones both endorse pairing Reta with a GH-support peptide (tesamorelin / CJC-1295 / ipamorelin) to preserve lean mass, and BPC-157/TB-500 (Wolverine (BPC-157 + TB-500)) for joints and recovery. Jones’s “Three Hands of the Aging Clock” longevity stack is Retatrutide (metabolic) + GHK-Cu (gene expression) + MOTS-c (mitochondrial), with his clinical mantra: low-and-slow Reta consistently beats high-dose Reta. Williams’s hardest rule for men: optimize hormones (TRT, thyroid, sleep) first — though that’s the bodybuilder/recomp frame; a lean longevity user running low-dose Reta with adequate protein and training does not need TRT first.

The two non-negotiables: protein and resistance training. A 100 kg person losing 25% body weight loses ~25 kg total, of which 5–7 kg will be lean mass — normal, but largely avoidable. Target ~1 g protein per pound of lean body mass (or Froese’s absolute targets: men 150–200 g/day, women 100–130 g/day) plus 2–3 resistance sessions/week. Without this, you get a smaller, weaker version of yourself instead of a leaner, stronger one.

Side effects & management

The mechanism explains the side effects, and the mechanism gives you the fixes. (Froese’s six-category framework + Williams’s mitigations.)

GI cluster — nausea (~27%), diarrhea (~23%), vomiting (~18%). Retatrutide “puts a brake pedal on your digestive highway” by slowing gastric emptying. Fix: slow titration (every 4 weeks minimum, 6–8 weeks better — slow titration reportedly cuts GI side effects ~79% vs rapid), smaller meals, limit liquids during meals, and aggressive hydration (GLP-1s blunt thirst, so people dehydrate). Sulfur burps are hydrogen-sulfide gas from food fermenting in the slowed gut — unpleasant, not dangerous; digestive enzymes help.

Fatigue + sleep + cramps — one cascade. This is Froese’s cleanest insight: the insulin drop signals the kidneys to dump sodium and water, so low blood sugar + low sodium + low water = exhaustion, and the same loop runs overnight. It’s the drug working, not failing. Fix: electrolytes — sodium + water as the primary lever, plus magnesium glycinate for the nervous-system/cardiac side. Magnesium oxide at night helps constipation (avoid daytime — it pulls water into the gut).

Elevated resting heart rate — the most distinctive Reta effect, ~5–10 BPM at higher doses (vs 2–4 with sema/tirz). The mechanism is specific: glucagon receptors sit on the heart’s natural pacemaker, the sinoatrial (SA) node, and Reta stimulates it directly. Pathologist Dr. Amin Hedayat frames the scale usefully — a +7–10 BPM rise at 12 mg is “~14,000 extra heartbeats a day… your heart running a half-marathon while you sit on the couch” — manageable for a healthy heart, but unproven long-term for anyone with underlying cardiac disease. Peaks around week 24, then partly declines. Fix: taurine 5–10 g/day (Williams: “every person on Reta needs taurine”) + magnesium glycinate + hydration, and Hedayat’s discipline — if resting HR keeps spiking, monitor it and titrate the dose down rather than pushing through (the strain accumulates silently). Persistent resting HR over 100, palpitations, irregular rhythm, or chest pain → pause and get evaluated.

Allodynia / skin sensitivity — 7% at lower doses, ~21% (1 in 5) at 12 mg in obesity trials, only ~2% at 12 mg in diabetics. Feels like sunburn without sun; glucagon receptors on sensory neurons temporarily lower the pain threshold. Fix: dial the dose back a few weeks then re-titrate; topical magnesium spray + hydration for acute relief.

Anhedonia / emotional flattening — a quieter, under-discussed effect: “you’ve silenced the food noise, but also some of the life noise.” Retatrutide modulates dopamine in the brain’s reward center (the nucleus accumbens), and at higher doses some users report hobbies, coffee, and everyday pleasures feeling flattened toward “grayscale” (Hedayat; mechanistically plausible but not trial-quantified). Fix: if mood or motivation noticeably dulls, dial the dose down and find the lowest effective dose — it’s a signal, not something to push through.

Muscle loss — covered above; protein + resistance training is the only real prevention. Hedayat adds a useful threshold: losing faster than ~2% of body weight per month tips the body into an emergency catabolic state, and replacing lost muscle is far harder than not losing it — target 1.2–1.5 g/kg protein (his conservative-clinical figure; Holyfield’s physique-optimization target runs higher, ~1 g/lb of goal weight) with leucine-rich sources.

Which muscles actually lose? The honest answer that addresses the “is this drug eating my heart or my gut?” fear (verified 2026-06-16). This is the most common GLP-1 concern, and the verified answer is reassuring:

• Skeletal muscle: REAL loss, manageable. SURMOUNT-1 DXA substudy (Look 2025, n=160, DOI 10.1111/dom.16275): at 72 weeks on tirzepatide, body weight dropped 21.3%, fat mass 33.9%, lean mass 10.9% — so ~75% of the weight loss came from fat, ~25% from lean mass. A 2025 Pharmacological Research class-level review (S1043661825003524) puts the lean-mass share at 20–30% of total weight loss across the GLP-1 class — consistent with placebo and typical caloric-restriction diet outcomes. The same review notes preclinical models show GLP-1 RAs protect skeletal muscle (intramuscular lipid down, mitochondrial health up) while human studies are mixed (some show excess lean-mass loss; some show sarcopenia protection). Bottom line: skeletal muscle loss is real but largely preventable with resistance training + adequate protein.

• Cardiac muscle: an honest nuance, not a hidden danger. Two domains of evidence:

  • In obesity-related HFpEF (heart-failure-with-preserved-ejection-fraction), LV mass reduction is BENEFICIAL remodeling, not harm. The SUMMIT trial CMR substudy (JACC 2024, PMID 39566869) found tirzepatide reduced LV mass by 11 g and paracardiac adipose tissue by 45 mL vs placebo, paralleling weight loss — unloading a hypertrophied heart is the goal in this population. STEP-HFpEF (semaglutide in HFpEF) showed favorable left-atrial remodeling, with HF events and symptoms improved. The HFpEF outcomes are net-positive.
  • In healthy users, a direct cardiomyocyte effect is observed in mice but the structural integrity and function are preserved. The University of Alberta semaglutide mouse study (JACC: Basic to Translational Science Oct 2024, PMID 39822607) found cardiomyocyte size + cardiac mass reductions in both lean and obese mice with no changes in wall thickness, septum thickness, fibrosis genes, or atrophy genes — and no functional impairment at rest. The honest gap: long-term cardiac-muscle data in healthy chronic GLP-1 users hasn’t been published yet. What we have: reassuring HFpEF data + reassuring short-term mouse data + no signal of human cardiac dysfunction at therapeutic doses. What we don’t have: 10-year human cardiac-muscle follow-up.

• Smooth muscle (esophagus, gut, vital organs): no published human evidence of dangerous loss at therapeutic doses with reasonable nutrition. The mechanism story is the hierarchical-preservation order under caloric deficit: fat goes first → skeletal muscle next (the protein reserve) → vital organ muscle and smooth muscle last (protected until extreme starvation). GLP-1 drugs induce a moderate, controlled caloric deficit — not the prolonged severe malnutrition that would deplete vital-organ structural protein. This hierarchical-preservation pattern is well-established physiology, observed in caloric-restriction studies and historical famine data alike.

Operational takeaway for the worried-friend audience: at therapeutic doses with reasonable nutrition, GLP-1 drugs primarily reduce skeletal muscle, which you can actively protect with resistance training + protein. Cardiac muscle effects exist but are net-beneficial in HFpEF and preserved-function in the available healthy-user data. Smooth muscle: no evidence of dangerous loss. Full verification record + study links in.

Rare but serious — know these. Gallstones (any rapid weight loss raises risk; sudden right-upper-quadrant pain after a fatty meal → evaluate) and pancreatitis (theoretical class risk, low actual rate; severe upper abdominal pain radiating to the back → go to a doctor). These are the two “don’t push through” red flags.

Oral-medication absorption. Like the rest of the GLP-1 class, retatrutide slows gastric emptying and can change how quickly oral drugs are absorbed. Usually minor; space or flag time-sensitive oral medications and discuss narrow-margin drugs with your prescriber.

Regulatory status

Investigational and not yet FDA-approved as of mid-2026; Phase 3 TRIUMPH trials are reading out, with Lilly reporting a successful TRIUMPH-4 readout and an NDA filing expected in the 2026–2027 window. Sold as a research-use-only compound. Not on the WADA-relevant approved-therapeutics list. The April-2023 GLP-1-class FDA shortage history is the backdrop for the compounded/research-chemical market it currently sits in.

The Alyve product

Alyve carries retatrutide in 10 mg ($104) and 20 mg ($164) vials (30 mg variant listed at $228, currently out of stock). Third-party COA from Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity confirmation): 99.01% on the 10 mg (lot RET750, net 10.47 mg) and 99.13% on the 20 mg (lot RET602, net 23.96 mg) — both identity-confirmed as retatrutide, net content beating label.

That matters more here than almost anywhere, because the gray market is rough: independent testing has found roughly 1 in 4 research peptides are underdosed, mislabeled, or contaminated — often with TFA salt left over from synthesis and no COA at all. A verified >99%-pure, identity-confirmed, US-handled product is the clean tier, and the COA is the proof.

Independent corroboration of the variability problem (2026-06-16). Fitness creator Ryan Humiston sent a research-grade Retatrutide vial labeled 60 mg for third-party analytical testing and the bottle came back at 108 mg actual content — 180% of label claim. The overdose direction is the same QC failure as the underdose direction (and arguably more dangerous for titration-discipline: a “0.5 mg” start dose calculated off that vial would actually be 0.9 mg, well into the GI-event range for many users). External validation of the same supply-chain thesis — verified-vendor + COA isn’t a marketing layer, it’s the difference between titration that works and titration that doesn’t. Cross-link to Tirzepatide for the compoundable-vs-not regulatory distinction (Tirz is compoundable via FDA-regulated 503A/503B pharmacies under shortage status; Reta is not).

Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. Three bottles is also close to a full titration-and-maintenance supply, so it’s how committed users actually buy.

Sources

• PMIDs 37366315 (NEJM Phase 2 obesity), 37385280 (Lancet Phase 2 T2D, dulaglutide comparator), 38858523 (Nat Med MASLD; PMC11271400), 40685589, 39305981, 39761578, 40291085, 41054801, 41056349.
• confirms the T2D comparator was dulaglutide (not metformin) and flags the misattributed “SURMOUNT = retatrutide” / “daily → 137% more AEs” claims (SURMOUNT is a tirzepatide program) as not supported — none of those claims appear in this article.
• Voy, HCPLive, Nature Medicine PMC, Lilly TRIUMPH-4 release.
• (lots RET750, RET602).
• Video digests: Williams masterclass (2026-06-03), Froese side-effects (2026-06-03), one practitioner masterclass (2026-06-01), Jones Reta/GHK/MOTS stack (2026-06-03), Hedayat pathologist explainer (2026-06-07) — (triple-lock mechanism, SA-node HR mechanism, anhedonia/nucleus-accumbens, 80%+ liver-fat framing, supply-chain “Russian Roulette”).
• Phase 3 TRIUMPH topline (2026-06-07 fact-check, vs full publications): Eli Lilly investor releases + AJMC / Pharmacy Times / BioPharma Dive coverage — TRIUMPH-1 (−28.3% at 80 wk, −30.3% at 104 wk in BMI ≥35, 45.3% ≥30%; May 2026) and TRIUMPH-4 (−28.7% at 68 wk; Dec 2025).
• TRIUMPH-4 knee-OA result (verified): trial-design paper Giblin et al., Diabetes Obes Metab 2026;28(1):83–93 — PMID 41090431, DOI 10.1111/dom.70209, PMC12673447, NCT05931367; topline pain/function efficacy via Lilly press release + medical-press coverage. Phase 2 obesity anchor confirmed: Jastreboff 2023 NEJM, DOI 10.1056/NEJMoa2301972, NCT04881760, PMID 37366315.

Cross-links: Tesamorelin · NAD+ · MOTS-c · Ipamorelin · Wolverine (BPC-157 + TB-500).